Sano’s platform powers
research into common disorders such as diabetes, eczema and depression, as well
as muscular dystrophy and other rare diseases.
The company, formerly known as Heterogeneous, has had 1,500 participants in its first year and aims to enrol more than 10,000 people by the end of the year. The company’s “transparent” platform empowers users by ensuring they remain in control of their DNA data.
passionate about the potential for personalised medicine based on genetic and
health data,” said Patrick Short, CEO of Sano Genetics. “Our platform
allows scientists to do research into personalised medicine, and access dynamic
health and genetic data sets, while still giving individuals transparency and
control throughout the process.”